Case Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.
Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 8 of 9
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
NCT00253448
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT00060203
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
NCT00054301
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
NCT00055640
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS
NCT00053287
Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00053300
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
NCT00049296
Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
NCT00253500
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
NCT00054236
Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
NCT00265889
Phase II Bevacizumab + Tax In Advanced Breast Cancer
NCT00027885
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
NCT00047021
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00041015
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
NCT00023790
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
NCT00028613
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00006465
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00054327
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00006864
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
NCT00007904
Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00006018
Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer
NCT00006877
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
NCT00006256
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00005981
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
NCT00006379
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00028665
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
NCT00006017
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
NCT00005647
SU5416 in Treating Patients With Advanced Solid Tumors
NCT00005642
Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
NCT00006255
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00005819
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
NCT00005822
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00006372
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
NCT00021151
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
NCT00006259
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00006378
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
NCT00004072
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00003567
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
NCT00004014
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
NCT00005997
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00003917
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00003953
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
NCT00003928
Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors
NCT00003768
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
NCT00005593
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
NCT00049439
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions
NCT00003336
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
NCT00003335
Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00003154
Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003110
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
NCT00003114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 116 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Case Comprehensive Cancer Center pipeline
55 recruiting of 407 indexed (14% open); 257 completed (63%).
Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Case Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Case Comprehensive Cancer Center page
407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.
- 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.